Literature DB >> 17581283

Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice.

Michael J Caulfield1, Li Shi, Su Wang, Bei Wang, Timothy W Tobery, Henryck Mach, Patrick L Ahl, Jayme L Cannon, James C Cook, Jon H Heinrichs, Robert D Sitrin.   

Abstract

Aluminum adjuvants are commonly used in prophylactic vaccines to enhance antigen immunogenicity through induction of high-titer antibody responses. Three major forms of aluminum adjuvants with substantially different physical and chemical properties have been described: aluminum phosphate (AlPO(4)), aluminum hydroxide (AlOH) and amorphous aluminum hydroxyphosphate sulfate (AAHS). Here we describe the effect of these different aluminum adjuvants on the formulation and subsequent immunogenicity in mice of virus-like particles (VLPs) consisting of the L1 protein of Human Papillomavirus (HPV) Type 16. Electron microscopy demonstrated that the physical appearance of the phosphate-containing aluminum adjuvants was markedly different from that of aluminum hydroxide. All three aluminum adjuvants were found to display unique surface charge profiles over a range of pH, while AAHS demonstrated the greatest inherent capacity for adsorption of L1 VLPs. These differences were associated with differences in immunogenicity: anti-HPV L1 VLP responses from mice immunized with AAHS-formulated HPV16 vaccine were substantially greater than those produced by mice immunized with the same antigen formulated with aluminum hydroxide. In addition, HPV L1 VLPs formulated on AAHS also induced a substantial interferon-gamma secreting T cell response to L1 peptides indicating the potential for an enhanced memory response to this antigen. These results indicate that the chemical composition of aluminum adjuvants can have a profound influence on the magnitude and quality of the immune response to HPV VLP vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581283     DOI: 10.4161/hv.3.4.4309

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  14 in total

1.  Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.

Authors:  Mark H Einstein; Mira Baron; Myron J Levin; Archana Chatterjee; Bradley Fox; Sofia Scholar; Jeffrey Rosen; Nahida Chakhtoura; Marie Lebacq; Robbert van der Most; Philippe Moris; Sandra L Giannini; Anne Schuind; Sanjoy K Datta; Dominique Descamps
Journal:  Hum Vaccin       Date:  2011-12-01

2.  Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.

Authors:  Mark H Einstein; Mira Baron; Myron J Levin; Archana Chatterjee; Bradley Fox; Sofia Scholar; Jeffrey Rosen; Nahida Chakhtoura; Dorothée Meric; Francis J Dessy; Sanjoy K Datta; Dominique Descamps; Gary Dubin
Journal:  Hum Vaccin       Date:  2011-12-01

Review 3.  An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.

Authors:  Alessio Facciolà; Giuseppa Visalli; Antonio Laganà; Angela Di Pietro
Journal:  Vaccines (Basel)       Date:  2022-05-22

4.  Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.

Authors:  Ting Fan Leung; Anthony Pak-Yin Liu; Fong Seng Lim; Franck Thollot; Helen May Lin Oh; Bee Wah Lee; Lars Rombo; Ngiap Chuan Tan; Roman Rouzier; Damien Friel; Benoit De Muynck; Stéphanie De Simoni; Pemmaraju Suryakiran; Marjan Hezareh; Nicolas Folschweiller; Florence Thomas; Frank Struyf
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Aluminum-induced entropy in biological systems: implications for neurological disease.

Authors:  Christopher A Shaw; Stephanie Seneff; Stephen D Kette; Lucija Tomljenovic; John W Oller; Robert M Davidson
Journal:  J Toxicol       Date:  2014-10-02

Review 6.  Clinical features in patients with long-lasting macrophagic myofasciitis.

Authors:  Muriel Rigolet; Jessie Aouizerate; Maryline Couette; Nilusha Ragunathan-Thangarajah; Mehdi Aoun-Sebaiti; Romain Kroum Gherardi; Josette Cadusseau; François Jérôme Authier
Journal:  Front Neurol       Date:  2014-11-28       Impact factor: 4.003

7.  Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus.

Authors:  Marzio Pennisi; Giulia Russo; Silvia Ravalli; Francesco Pappalardo
Journal:  BMC Bioinformatics       Date:  2017-12-28       Impact factor: 3.169

8.  BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.

Authors:  Anne K Barasa; Peng Ye; Meredith Phelps; Ganapathiram T Arivudainambi; Timelia Tison; Javier Gordon Ogembo
Journal:  Oncotarget       Date:  2017-05-23

9.  Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.

Authors:  Ligia A Pinto; Joakim Dillner; Simon Beddows; Elizabeth R Unger
Journal:  Vaccine       Date:  2018-02-01       Impact factor: 3.641

10.  Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil.

Authors:  Rotem Inbar; Ronen Weiss; Lucija Tomljenovic; Maria-Teresa Arango; Yael Deri; Christopher A Shaw; Joab Chapman; Miri Blank; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 4.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.